Why Avoid Live Vaccines on Cosentyx
Cosentyx (secukinumab), an IL-17 inhibitor for psoriasis, psoriatic arthritis, and ankylosing spondylitis, suppresses immune responses. Live vaccines contain weakened live viruses or bacteria that replicate in the body, risking uncontrolled infection in immunocompromised patients. Avoid live vaccines during therapy and for varying periods before/after.[1][2]
Which Live Vaccines Are Restricted
Common examples include:
- MMR (measles, mumps, rubella)
- Varicella (chickenpox)
- Zoster (shingles, e.g., Zostavax; note: recombinant Shingrix is inactivated and allowed)
- Oral polio, rotavirus, yellow fever, and live nasal flu vaccines
Inactivated or subunit vaccines (e.g., flu shot, HPV, COVID-19) are generally safe and recommended.[1][3]
Timing Rules for Vaccination
- Before starting Cosentyx: Complete live vaccines 4–6 weeks prior to first dose.
- During therapy: Do not administer live vaccines.
- After stopping Cosentyx: Wait 4–6 weeks post-last dose before live vaccines; some guidelines extend to 3–6 months based on immune recovery.[1][2][4]
Consult vaccination records and test immunity if unsure.
What If You've Already Had a Live Vaccine
Report recent live vaccination to your doctor before starting Cosentyx. Therapy may need delay or monitoring for infection signs like fever, rash, or lymph node swelling.[2]
Exceptions and Special Cases
- Bridging therapy (e.g., methotrexate) may alter risks—discuss with rheumatologist or dermatologist.
- Travel requirements (e.g., yellow fever) need case-by-case approval; alternatives or delays often preferred.
- Children or pregnant patients: Extra caution; live vaccines contraindicated.[3][4]
No routine monitoring tests recommended, but watch for immunosuppression signs.
Doctor's Role and Patient Steps
Always inform providers of Cosentyx use before any vaccination. Get annual inactivated flu/pneumococcal shots. For emergencies, weigh risks with infectious disease specialist.[1][2]
[1]: Cosentyx Prescribing Information (Novartis)
[2]: FDA Label for Secukinumab
[3]: CDC Live Vaccine Guidelines for Immunocompromised
[4]: ACR Guidelines on Vaccinations in Rheumatic Diseases